XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Lease Term and Discount Rate

Financing liability information was as follows (dollars in thousands):

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Weighted average remaining lease term (in years)

 

 

17.8

 

 

 

18.8

 

Weighted average discount rate

 

 

9.0

%

 

 

9.0

%

Lease information was as follows (dollars in thousands):

 

 

December 31, 2023

 

 

December 31, 2022

 

Operating lease right-of-use assets(1)

 

$

4,685

 

 

$

6,714

 

 

 

 

 

 

 

 

Operating lease liability-current(2)

 

$

1,423

 

 

$

1,304

 

Operating lease liability-long-term

 

 

3,925

 

 

 

5,343

 

Total

 

$

5,348

 

 

$

6,647

 

 

 

 

 

 

 

 

Weighted average remaining lease term (in years)

 

 

3.7

 

 

 

4.6

 

Weighted average discount rate

 

 

7.3

%

 

 

7.3

%

__________________________

(1)
Operating right-of-use assets related to vehicles, offices and the manufacturing facility are included in other assets in the consolidated balance sheets.
(2)
Operating lease liability – current are included in accrued expenses and other current liabilities in the consolidated balance sheets.
Summary of Lease Information

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Interest expense on financing liability

 

$

9,825

 

 

$

9,758

 

 

$

1,373

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

Operating lease costs

 

$

1,675

 

 

$

1,525

 

 

$

863

 

Variable lease costs

 

 

104

 

 

 

274

 

 

 

515

 

Cash paid

 

 

1,068

 

 

 

1,823

 

 

 

1,867

 

Summary of Financing Liability Payments

The Company's remaining financing liability payments were as follows (in thousands):

 

 

December 31, 2023

 

2024

 

$

10,018

 

2025

 

 

10,269

 

2026

 

 

10,533

 

2027

 

 

10,849

 

2028

 

 

11,174

 

Thereafter

 

 

177,278

 

Total

 

 

230,121

 

Interest payments

 

 

(123,318

)

Debt issuance costs

 

 

(2,675

)

Total financing liability

 

$

104,128

 

Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements The Company's remaining purchase commitments and estimated capacity fee liability as of December 31, 2023, as well as pre-amendment purchase commitments as of September 30, 2023, were as follows (€ in millions):

 

December 31, 2023

 

 

September 30, 2023

 

 

Remaining Purchase Commitments

 

 

Estimated Capacity Fees

 

 

Remaining Purchase Commitments

 

2023

 

 

 

 

 

 

 

2.4

 

2024

 

2.9

 

 

 

 

 

 

14.6

 

2025

 

 

 

 

1.5

 

 

 

15.5

 

2026(1)

 

4.2

 

 

 

2.0

 

 

 

19.4

 

2027

 

6.0

 

 

 

1.0

 

 

 

9.2

 

2028

 

6.0

 

 

 

1.0

 

 

 

 

2029

 

6.0

 

 

 

1.0

 

 

 

 

2030

 

6.0

 

 

 

1.0

 

 

 

 

2031

 

8.0

 

 

 

0.5

 

 

 

 

2032

 

8.0

 

 

 

0.5

 

 

 

 

2033

 

8.0

 

 

 

0.5

 

 

 

 

2034

 

4.4

 

 

 

0.5

 

 

 

 

Total

 

59.5

 

 

 

9.5

 

 

 

61.1

 

__________________________

(1)
If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of 750,000 per quarter that the product is not available for purchase.
Schedule of Future Minimum Office And Vehicle Lease Payments

The Company's future minimum office and vehicle lease payments were as follows (in thousands):

 

 

 

December 31, 2023

 

2024

 

$

1,496

 

2025

 

 

1,861

 

2026

 

 

1,140

 

2027

 

 

1,072

 

2028

 

 

643

 

Total

 

 

6,212

 

Interest expense

 

 

(864

)

Total operating lease liability

 

$

5,348